3950-10-5

Usage

Uses

Used in Pharmaceutical Synthesis:
1,6-Dihydro-4-hydroxy-2-methyl-6-(oxo)nicotinic acid ethyl ester is used as an intermediate in the synthesis of various pharmaceuticals due to its unique chemical structure and potential medicinal properties.
Used in Anti-inflammatory Applications:
In the medical field, 1,6-Dihydro-4-hydroxy-2-methyl-6-(oxo)nicotinic acid ethyl ester is being studied as an anti-inflammatory agent, potentially offering relief for conditions characterized by inflammation.
Used in Cardiovascular Applications:
1,6-Dihydro-4-hydroxy-2-methyl-6-(oxo)nicotinic acid ethyl ester is also being investigated for its effects on the cardiovascular system, suggesting it may have a role in managing or treating heart-related conditions.
Used in Neurodegenerative Disorder Treatment:
1,6-Dihydro-4-hydroxy-2-methyl-6-(oxo)nicotinic acid ethyl ester is being explored as a potential treatment for neurodegenerative disorders, indicating its possible neuroprotective or restorative capabilities.
Further research is necessary to fully elucidate the mechanisms of action and the breadth of applications for 1,6-Dihydro-4-hydroxy-2-methyl-6-(oxo)nicotinic acid ethyl ester in medicinal and pharmaceutical contexts.

Upstream product

• 15781-70-1 malonic acid bis-(2,4,6-trichloro-phenyl) ester 
• 626-34-6 ethyl aminocrotonate 
• 626-34-6 ethyl 3-aminobut-2-enoate 

Downstream Products

• 1044870-32-7 7-(4-hydroxy-3,5-dimethylphenyl)-2,4-dimethoxy-1,6-naphthyridin-5(6H)-one 
• 1044870-91-8 2,4-dimethoxy-7-(4-methoxy-3,5-dimethylphenyl)-1,6-naphthyridin-5(6H)-one 
• 1044870-33-8 7-(4-hydroxy-3,5-dimethylphenyl)-2,4-dimethoxy-1,6-naphthyridin-5(6H)-one hydrochloride 
• 1044871-08-0 7-(4-hydroxy-3,5-dimethylphenyl)-2,4-diisopropoxy-1,6-naphthyridin-5(6H)-one 
• 1044872-53-8 7-(4-benzyloxy-3,5-dimethyl-phenyl)-2,4-diisopropoxy-6H-[1,6]naphthyridin-5-one 
• 1044870-74-7 7-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-2,4-dimethoxy-1,6-naphthyridin-5(6H)-one 
• 1391418-86-2 4-{[2-(2,6-dichlorobenzyl)-5-oxo-5,6-dihydro-1,6-naphthyridin-4-yl]amino}-3-methoxy-N-[3-(morpholin-4-yl)propyl]benzamide 
• 1391419-35-4 4-(2-(2,6-dichlorobenzyl)-5-oxo-5,6-dihydro-1,6-naphthyridin-4-ylamino)-3-methoxybenzoic acid 
• 1391419-32-1 2-(2,6-dichlorobenzyl)-4-(4-(hydroxymethyl)-2-methoxyphenylamino)-1,6-naphthyridin-5(6H)-one 
• 1391419-30-9 2-chloro-4-(4-(hydroxymethyl)-2-methoxyphenylamino)-1,6-naphthyridin-5(6H)-one 
• 1390658-91-9 tert-butyl 4-(4-((2-(2,5-difluorobenzyl)-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate 
• 1390656-28-6 2-(2-fluorobenzyl)-4-{[2-methoxy-4-(piperidin-4-yl)phenyl]amino}pyrido[2,3-d]pyridazin-5(6H)-one 
• 1390658-08-8 tert-butyl 4-(4-((2-(2-fluorobenzyl)-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate 
• 1390658-03-3 tert-butyl 4-(4-(2-(2-cyclopropylethyl)-5-oxo-5,6-dihydropyrido[3,2-d]pyridazin-4-ylamino)-3-methoxyphenyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

Used for the prevention and treatment of cardiovascular diseases

The invention relates to compounds that can be used for adjusting the expression of apolipoprotein A-I (ApoA-I) and usage of the compounds in treating and preventing cardiovascular diseases and related diseases, including the disorder related to cholesterol or lipids such as atherosclerosis.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.

Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-iodopyridin-2(1H)-one type anti-HIV agents

A series of C-5 methyl substituted 4-arylthio- and 4-aryloxy-3-iodopyridin- 2(1H)-ones has been synthesized as new pyridinone analogues for their evaluation as anti-HIV inhibitors. The optimization at the 5-position was developed through an efficient use of the key intermediates 5-ethoxycarbonyl- and 5-cyano-pyridin-2(1H)-ones (14 and 15). Biological studies revealed that several compounds show potent HIV-1 reverse transcriptase inhibitory properties, for example, compounds 93 and 99 are active at 0.6-50 nM against wild type HIV-1 and a panel of major simple/double HIV mutant strains.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotei? A-I (ApoA-l), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES

The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

3-SUBSTITUTED-6-ARYL PYRIDINES

3-substituted-6-aryl pyridines of Formula (I) are provided: Formula (I) wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula (I) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.